Drug-coated balloon catheter that Maeda Corporation aims to sell in 2010

Drug-coated balloon catheter that Maeda Corporation aims to sell in 2010

Maeda Kosen has invested about 2.2 billion yen in MedAlliance, a Swiss medical device venture, and signed an agreement to exclusively market a new drug-coated balloon for the treatment of peripheral artery disease in Japan. The company believes that the new drug will be highly effective in catheterizing blood vessels for lower limb artery disease from the waist down, and aims to start clinical trials in Japan in 2020 and sales in 2010. MedAlliance, established in 2008, has the technology to apply sirolimus, an immunosuppressant agent, to the film material of the balloon. The technology applies sirolimus when the balloon is expanded in the blood vessel to prevent the onset of re-narrowing after the procedure. The balloon will be named "Celluon" and is planned to be sold worldwide around 2010. Maeda Kosen will be responsible for introducing it in Japan. Photo taken on June 28, 2019, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images

  • Product Code
  • ILEA000687761
  • Registered date
  • 2019/6/28 00:00:00
  • Credit
  • THE NIKKAN KOGYO SHIMBUN / Kyodo News Images
  • Media source
  • THE NIKKAN KOGYO SHIMBUN
  • Media size
  • 1743 × 1643 pixel
  • Resolution
  • 72 dpi
  • Deployment size
  • 1.68(MB)*
  • Special instruction
  • **The text may be generated by an automatic translation system**

*File size when opened in Photoshop, etc.

Similar Images & Videos
    UNIQLO Opens Next-Generation Store in Harajuku

    UNIQLO Opens Next-Generation Store in Harajuku

    On March 3, UNIQLO revealed to the press the UNIQLO Harajuku Store (photo), an urban store that will open in the commercial complex Wiz Harajuku (Jingumae, Shibuya-ku) on March 5. This is the first store to open in the Harajuku area in eight years. The store will be the first UNIQLO store in the Harajuku area in eight years to combine the virtual and the real, and will feature a sales floor linked to an application that allows customers to search for clothing styles. The company has also launched a service that alerts customers to the location of products they are interested in on the display. (June 3, 2020, Shibuya Ward, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
      Shionogi's new mid-term management plan briefing

      Shionogi's new mid-term management plan briefing

      On the 1st, Shionogi announced a new mid-term management plan to invest 500 billion yen in expanding overseas business and launching new businesses by FY2024. The company will also increase research and development expenses by 20% over the past five years to about 342.1 billion yen. In addition to strengthening its own sales of pharmaceuticals in Japan and overseas, the company will also invest heavily in products and services other than ethical drugs, such as vaccines.In terms of sales strategy, the company plans to strengthen its sales in the U.S. and China, and increase the ratio of overseas sales to more than 50% in FY2012 (18.5% in FY2007). President Tedairogi said, "We aim to become a drug discovery company that people from outside the company want to work with," and also indicated that the company will place importance on alliance strategies. (Photo taken on June 1, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
        KM Biologics begins development of vaccine for novel coronavirus

        KM Biologics begins development of vaccine for novel coronavirus

        KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
          Technology to etch Kai semiconductor with fluoroplastic instead of CFC gas

          Technology to etch Kai semiconductor with fluoroplastic instead of CFC gas

          The established technology will be used for dry etching, thin film formation and cleaning of silicon. Easy-to-handle gases such as argon and nitrogen are irradiated onto solid fluoropolymers to generate fluorine-containing gas. The gas is then used for plasma treatment. Using a proto device with electrodes developed for special equipment, the company irradiated nitrogen gas and etched a glass substrate, and was able to etch 40 nanometers in one minute. The company plans to achieve an etching speed of 200 nanometers for commercialization. Plasma is an unstable state in which electrons have been removed from molecules, and it modifies the surface of materials, improving adhesion and cleaning effects. (Photo taken on March 30, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
            Tohoku University and TEPCO to conduct joint research on decommissioning

            Tohoku University and TEPCO to conduct joint research on decommissioning

            The term is five years. The division will conductresearch in a wide range of fields to solve various technical problems at the decommissioning site, including evaluation technology to detect the aging deterioration of structures. With the aim of fostering human resources, a CFReND branch office will be established at the Fukushima Daiichi Nuclear Power Plant site this summer. On-site exchanges of opinions between engineers at the decommissioning site and Tohoku University faculty and graduate students will be promoted. Nobuyoshi Hara, vice president of Tohoku University (photo at right), says, "We will continue our efforts to promote decommissioning. (Photo taken on March 24, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
              Foxter's Hybrid Image Processing System for AI Visual Inspection

              Foxter's Hybrid Image Processing System for AI Visual Inspection

              Foxter Corporation (Toyonaka City, Osaka Prefecture) will release in May a hybrid image processing system that combines Preferred Networks' (PFN, Chiyoda Ward, Tokyo) artificial intelligence (AI) visual inspection and conventional image processing methods.The company will market the system in Japan and China in cooperation with a subsidiary of the OPTEX Group, which is engaged in the manufacture of lighting for image processing, in terms of sales and service. The sales target is 200 units a year. Auto parts manufacturers and others have already begun to introduce the system on a trial basis. The device in the center of the photo is the AI Stellar Controller. (Photo taken on March 16, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                Musashi Seimitsu Kogyo's AI Visual Inspection System

                Musashi Seimitsu Kogyo's AI Visual Inspection System

                Currently, the company is introducing the inspection machine in the mass production line of its own plant, and when it sells the machine externally, it intends to make the price of the machine equivalent to the labor cost for inspection. In the future, Musashi Seimitsu will further improve the versatility of the AI algorithm so that multiple types of parts can be inspected with a single device. Musashi Seimitsu's mainstay products are gears, ball joints and other automotive drive components. In recent years, the company has been focusing on new businesses and is accelerating its efforts in the AI field, including the establishment of a joint venture with an Israeli AI venture in 2019. In the future, the company aims to achieve sales of 100 billion yen through new businesses. Photo taken on February 21, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images
                  Shinkawa Electric's vibration monitoring sensor "Zerk X8

                  Shinkawa Electric's vibration monitoring sensor "Zerk X8

                  The connected sensors acquire analog data such as temperature, pressure, water level and flow rate as well as vibration. The data is sent via wireless LAN to an antenna several dozen meters away. The data is collected in the "Machine Dossier" cloud system. The data is displayed in an easy-to-understand manner using graphs and other data. Amazon's Amazon Web Services (AWS) is used as the system infrastructure. The data can be easily viewed on smartphones and other devices. The annual fee for using the system is 48,000 yen (excluding consumption tax) for each eight-point sensor. SEC of America (North Carolina), a wholly owned subsidiary in the U.S., develops and produces the system. Shinkawa Sensor Technology (Chiyoda Ward, Tokyo), a subsidiary in Japan, will develop and produce higher-specification non-contact vibration sensors. (Photo taken on February 6, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                    Nihon Vital's "Kaisei".

                    Nihon Vital's "Kaisei".

                    Taking a hint from the fact that insects find flowers by the wavelength and light intensity of sunlight, the company has developed an "insect eye sensor" that tracks sunlight. It efficiently collects sunlight. The six optical fibers can be extended up to one kilometer and can illuminate 500 square meters. It is about 2 meters long, 2 meters wide and 2.5 meters high. The price starts at 5 million yen (excluding consumption tax). It has been used in buildings and train stations in Kumamoto Prefecture, and its sales have been about 100 million yen. It can also be used to cut infrared rays and ultraviolet rays. The company is currently producing them overseas, but will switch to domestic production within this year. The price will start at 250,000 yen (same as above). "The market for solar concentrators is worth about 20 billion yen. President Yokozawa hopes to capture a 20% share of this market. (Photo taken on December 19, 2019, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                      University of Electro-Communications and Obayashi Corporation's diagnostic device for correcting blurred images

                      University of Electro-Communications and Obayashi Corporation's diagnostic device for correcting blurred images

                      Associate Professor Norihiro Koizumi of the University of Electro-Communications and Obayashi Corporation (Bunkyo-ku, Tokyo) have developed a device that uses artificial intelligence (AI) and robotic technology to correct blurring caused by the movement of organs and assist in taking clear images using ultrasound. It is expected that Obayashi Corporation will start selling this device in April 2022 at a price of tens of millions of yen, for use as a supplement to ultrasound diagnostic equipment. In the future, it is envisioned that cancer treatment using radiation or heavy particle beams will be carried out while observing in real time. It is expected that by obtaining images that pinpoint the location of organs, the beam can be accurately irradiated to the affected area. Image taken on December 19, 2019, credit: Nikkan Kogyo Shimbun / Kyodo News Images